High Correlation between Glaucoma Treatment with Topical Prostaglandin Analogs and BDNF Immunoreactivity in Human Retina

Matthew M Harper; Erin A Boese; Randy H Kardon; Johannes Ledolter; Markus H Kuehn

doi:10.1080/02713683.2020.1822417

Back

High Correlation between Glaucoma Treatment with Topical Prostaglandin Analogs and BDNF Immunoreactivity in Human Retina

Journal article

Open access

Peer reviewed

High Correlation between Glaucoma Treatment with Topical Prostaglandin Analogs and BDNF Immunoreactivity in Human Retina

Matthew M Harper, Erin A Boese, Randy H Kardon, Johannes Ledolter and Markus H Kuehn

Current eye research, Vol.46(5), pp.739-745

05/04/2021

DOI: 10.1080/02713683.2020.1822417

PMID: 32985274

Files and links (1)

url

https://figshare.com/articles/dataset/High_Correlation_between_Glaucoma_Treatment_with_Topical_Prostaglandin_Analogs_and_BDNF_Immunoreactivity_in_Human_Retina/13013086View

Open Access

Abstract

To examine the expression of brain-derived neurotrophic factor (BDNF) and its high-affinity receptor, tropomyosin-related kinase receptor-B (TrkB), in normal and glaucomatous human retinas. Human retinas were collected from 8 donors who had been clinically diagnosed and treated for glaucoma, and from 9 control donors. Immunohistochemical analysis for BDNF and TrkB was performed. The percent of each retina expressing BDNF and TrkB was quantified for the total retinal thickness, and separately for the retinal ganglion cell (RGC) complex + retinal nerve fiber layer (RNFL). The expression of each protein was correlated with clinical outcomes obtained from the subject's ocular histories. There was no significant difference in BDNF or TrkB expression when comparing glaucomatous and control retinas. Correlation analysis revealed a significant relationship between BDNF expression and the use of prostaglandin analogs. TrkB expression was highly correlated with the last-measured intraocular pressure (IOP), the use of carbonic anhydrase inhibitors, the use of beta blockers, and the total number of drugs used for the treatment of glaucoma. Topical drugs used to treat glaucoma were associated with an increase in retinal BDNF and TrkB expression in human retina, independent of IOP, which may represent molecular evidence of neuroprotective pathway activation.

TrkB

neurotrophin

BDNF

retina

glaucoma

neurotrophin receptor

Details

Title: Subtitle: High Correlation between Glaucoma Treatment with Topical Prostaglandin Analogs and BDNF Immunoreactivity in Human Retina
Creators: Matthew M Harper - Veterans Administration Center for the Prevention and Treatment of Visual Loss, VA Medical Center
Erin A Boese - Carver College of Medicine, the University of Iowa
Randy H Kardon - Veterans Administration Center for the Prevention and Treatment of Visual Loss, VA Medical Center
Johannes Ledolter - The University of Iowa Tippie College of Business
Markus H Kuehn - Veterans Administration Center for the Prevention and Treatment of Visual Loss, VA Medical Center
Resource Type: Journal article
Publication Details: Current eye research, Vol.46(5), pp.739-745
DOI: 10.1080/02713683.2020.1822417
PMID: 32985274
NLM abbreviation: Curr Eye Res
ISSN: 0271-3683
eISSN: 1460-2202
Publisher: Taylor & Francis
Grant note: DOI: 10.13039/100000738, name: the Department of Veterans Affairs, award: RX003002; name: US National Institute of Health, award: P30 EY025580
Language: English
Date published: 05/04/2021
Academic Unit: Statistics and Actuarial Science; Iowa Neuroscience Institute; Biology; Business Analytics; Ophthalmology and Visual Sciences
Record Identifier: 9984070275402771

Metrics

27 Record Views

7 Times Cited - Web of Science